Claims

[Claim 1]

Use of an aripiprazole intramuscular (IM) depot formulation comprising from about 10 mg to about 500 mg of aripiprazole in the manufacture of a medicament for treatment of schizophrenia or bipolar disorder I, wherein the medicament comprises:

two, separate injections of the aripiprazole intramuscular (IM) depot formulation, wherein each injection comprises from about 10 mg to about 500 mg of aripiprazole, and wherein each injection is to be administered at an injection site chosen from a gluteal site, a deltoid site, and combinations thereof, and

a single dose of oral aripiprazole,

wherein the medicament is to be administered on a first day of an aripiprazole treatment.

[Claim 2]

The use according to claim 1, wherein each of the two, separate injections comprises 400 mg of aripiprazole.

[Claim 3]

The use according to claim 1 or 2, wherein the medicament further comprises a single, maintenance injection of the aripiprazole IM depot formulation to be administered monthly after the first day of the aripiprazole treatment.

[Claim 4]

The use according to claim 3, wherein the single, maintenance injection is chosen from about 300 mg and about 400 mg of aripiprazole in the aripiprazole IM depot formulation.

[Claim 5]

The use according to claim 4, wherein the single, maintenance injection comprises about 400 mg of aripiprazole.

[Claim 6]

The use according to any one of claims 3 to 5, wherein the single, maintenance injection is to be administered no sooner than 26 days after the first day of the aripiprazole treatment.

[Claim 7]

The use according to claim 3, wherein the single, maintenance injection is chosen from 160 mg and 200 mg of aripiprazole in the aripiprazole IM depot formulation when the medicament is to be administered to a patient who is a poor CYP2D6 metabolizer or has been taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors for greater than 14 days.

[Claim 8]

The use according to any one of claims 1 to 5, wherein the two, separate injections of the aripiprazole IM depot formulation are to be administered at separate gluteal and/or deltoid injection sites.

[Claim 9]

The use according to claim 8, wherein the two, separate injections of the aripiprazole IM depot formulation are to be administered at separate gluteal injection sites.

[Claim 10]

The use according to claim 8, wherein the two, separate injections of the aripiprazole IM depot formulation are to be administered at gluteal and deltoid injection sites.

[Claim 11]

The use according to claim 8, wherein the two, separate injections of the aripiprazole IM depot formulation are to be administered at separate deltoid injection sites.

[Claim 12]

The use according to any one of the preceding claims, wherein the single dose of oral aripiprazole ranges from about 2 mg to about 30 mg of aripiprazole.

[Claim 13]

The use according to claim 12, wherein the single dose of oral aripiprazole ranges from about 10 mg to about 30 mg.

[Claim 14]

The use according to claim 12, wherein the single dose of oral aripiprazole is 20 mg.

[Claim 15]

The method according to claim 12, wherein the single dose of oral aripiprazole is 10 mg.

[Claim 16]

The use according to claim 1, wherein each of the two, separate injections comprises about 300 mg of aripiprazole and the single dose of oral aripiprazole is about 20 mg when the medicament is to be administered to a patient who is a poor CYP2D6 metabolizer.

[Claim 17]

The use according to any one of the preceding claims, wherein the aripiprazole is in the form of a salt.